Fresenius Medical Care AG (FMS) FinancialsFMSFresenius Medical Care AG

Fresenius Medical Care AG (FMS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Care Delivery, accounting for 68.8% of total sales, equivalent to $3.71B. Other significant revenue streams include Care Enablement and Value based care. Understanding this composition is critical for investors evaluating how FMS navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Fresenius Medical Care AG maintains a gross margin of 26.95%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 10.13%, while the net margin is 6.03%. These profitability ratios, combined with a Return on Equity (ROE) of 7.23%, provide a clear picture of how effectively FMS converts its operational activities into shareholder value.

In the context of the broader market, FMS competes directly with industry leaders such as ENSG and DVA. With a market capitalization of $12.38B, it holds a leading position in the sector. When comparing efficiency, FMS's gross margin of 26.95% stands against ENSG's 14.47% and DVA's 27.98%. Such benchmarking helps identify whether Fresenius Medical Care AG is trading at a premium or discount relative to its financial performance.

The company reported Q2 revenue of €4.86 billion with a 5% organic growth, and a gross margin of 26.95%, indicating solid profitability. However, the net income in Q2 was $253.7 million, showing fluctuations in earnings.